



JMCC/ISHR Community,

We, the editorial team at JMCC, wish you all stay safe and well during the pandemic of COVID-19. We would like to communicate with you about the new efforts at JMCC to support the discovery and dissemination of the rapid scientific progress in research about COVID-19.

JMCC will initiate a virtual special issue on Cardiovascular Implications in COVID-19 with related papers, including letters to editor, short communications, reviews and full research articles. Considering the urgent need for new information from the scientific community and general public, and to promote the rapid dissemination of findings in the field, these submissions will be handled with expedience, but absolutely without compromise to rigor, by a dedicated editorial team and reviewers. Not exhaustively, the specific topics of particular interest for JMCC include:

- 1). More and better demonstration of serum markers and cardiovascular features to differentiate COVID-19 diagnosis, as well as prognosis, AND informing the mechanisms of disease pathogenesis, as well as risk of mortality, among the prevailing hypotheses such as myocarditis injury, microvascular injury, hypoxic injury, pulmonary hypertension and RV failure.
- 2). Better and new understanding to cardiovascular complications associated with Covid19, including heart failure, pulmonary hypertension, hypoxia, acute viral injury and arrhythmia, including clinical or laboratory evidence based on cellular studies, with emphasis on cell-based systems prior to animal models.
- 3). A focus on COVID-19 related to ACE2 function, including ACE2 expression, RAS function and RASi therapy in COVID-19 management, including molecular and cellular evidence to support novel hypothesis using cutting-edge tools, such as single cell gene expression analysis. Cellular responses to COVID-19 infection in ACE2 expressing cells in the CV system.
- 4). Post-COVID-19 cardiovascular recovery and continuing susceptibility to other CV diseases, long-term monitoring and screening for CV health in post-COVID-19 patients.
- 5). Cardiovascular complications from currently tested anti-COVID-19 treatments, including Remdesivir, Lopinavir/Ritonavir, Chloroquine (in particular), glucocorticoid, IVIG and tocilizumab et al, demonstrated at molecular and cellular level.
- 6). Interactions between CVD and other co-morbidities of COVID-19, mechanistic investigation in cell based system at cellular and molecular levels.

If you have questions regarding a potential topic related to COVID-19, please reach out to the editorial team.